Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC) -- Ignore unavailable to you. Want to Upgrade?

To: Tod C who wrote (777)	6/15/1998 10:30:00 PM
From: Just-a-thought	Read Replies (1) \| Respond to of 5402

SANGUINE CORP. (SGNC) a California corporation is engaged in the development of a synthetic red blood cell product call "PHER-02." Management believes the PHER-02 has advantages over human blood: It can be sterilized to be free of disease including (HIV): is belived to have the quality of a universal match for all blood types: can be mass-produced: and may be stored much longer than human blood. Sanguine estimates the annual market potential for this product at $20 billion. Dr. Thomas C. Drees: Company President & Chief Executive Officer >>>>>>>>>>>>>>>>> Business Wire SANGUINE FUNDS BATTELLE PROPOSAL TO CONDUCT FURTHER TESTING IN THE DEVELOPMENT OF A BLOOD SUBSTITUTE ------------------------------------------------------------------------ PASADENA, Calif.--(BUSINESS WIRE)--May 4, 1998--Sanguine Corp. (OTC BB:SGNC.O) has lined up and committed funding for a proposal by Battelle Memorial Research Institute to further animal testing of emulsions for use as oxygen-carrying blood substitutes. Battelle, the world's oldest and biggest independent contract research group of scientists, engineers, and other specialists, has provided research since 1994 in support of Sanguine's efforts to develop, manufacture and market a proprietary synthetic red blood cell substitute. According to Dr. Thomas C. Drees, president and chief executive officer of Sanguine Corp., "The AIDS epidemic as well as the rising level of demand for blood worldwide have created a significant market opportunity for a safe blood substitute. Sanguine estimates the annual market potential for this product at $20 billion." The author of Blood Plasma: the Promise and the Politics, Drees has been in the forefront of the artificial blood products field for more than 20 years. --30--kjs/ix* CONTACT: mklpr, Salt Lake City Mary Kay Lazarus, 801/328-8899 KEYWORD: CALIFORNIA INDUSTRY KEYWORD: MEDICINE PRODUCT Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. URL: businesswire.com Copyright 1998, Business Wire >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> SGNC Sanguine Corp. Info Thread on 'SI': Subject 21537 Battelle home page: battelle.org